Anil Goyal

Dr. Goyal, has 24+ years of senior management and leadership experience at several public and private biotechnology companies where he has raised >$200M from public / private investors / federal sources, completed >$1B in pharma deals, and accomplished several exits. Prior to joining IMMvention in 2017, he was COO at Ribometrix where he raised Ribometrix's first venture funding. His other biotech experience includes leading company formation, fundraising, business development, M&A, strategic planning, and senior management roles at Heat Biologics (HTBX), Serenex (led acquisition/sale to Pfizer), Optherion (led acquisition/sale to Sequenom and Baxter), Qualiber, Ascletis (public company on Hong Kong market) and Millennium Pharmaceuticals (acquired by Takeda). He is currently a board member/advisor to Enzerna Biosciences, MimiVax, and UNC-Chapel Hill KickStart Program.

He has experience building and growing companies with small molecule, antibody, siRNA, gene, and cell therapies across many therapeutic areas including immuno-oncology, ophthalmology, and inflammation.

Dr. Goyal received his Ph.D. degree in Microbiology and Molecular Genetics jointly from Rutgers, The State University and University of Medicine and Dentistry of New Jersey. He completed post-doctoral fellowships at the NJ Center for Agriculture & Environment and Merck & Co.

​Anil roved the World (pre-COVID) to find the hottest sauce for his collection.